Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE)
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
To evaluate whether palifermin (rHuKGF) administered as a single dose is non-inferior to 3
consecutive doses of palifermin in reducing the incidence of severe oral mucositis (World
Health Organization [WHO] grade 3 and 4).